Core Scientific, Inc. Form 8-K Summary
Business Context and Reporting Period
Core Scientific, Inc. filed this Form 8-K on July 21, 2022, reporting an agreement dated July 20, 2022, with B. Riley Principal Capital II, LLC. The filing concerns a potential equity financing facility, not quarterly or annual financial results.
Key Financial and Capital Markets Terms
- The company may elect to sell up to $100 million of common stock to B. Riley over a 24-month period beginning when specified commencement conditions are satisfied.
- Sales are entirely at the company’s discretion; the company is not obligated to sell any shares.
- Purchase prices will generally be based on Nasdaq volume-weighted average prices, less a fixed 3% discount.
- Regular and intraday purchases are generally limited to the lesser of 3 million shares or 20% of the applicable Nasdaq trading volume.
- Nasdaq rules limit issuance under the agreement to 70,289,880 shares, approximately 19.99% of shares outstanding before execution, unless stockholder approval is obtained or the applicable average purchase price is at least $1.75 per share.
- B. Riley’s beneficial ownership resulting from purchases may not exceed 4.99% of outstanding common stock.
- Core Scientific issued B. Riley 573,381 commitment shares upon execution and reimbursed $75,000 of legal fees and disbursements.
- The filing does not provide revenue, profit, cash-flow, margin, debt, liquidity, or other operating-performance figures for the reporting period.
Material Changes Versus the Prior Comparable Period
The filing text does not provide a prior-period comparison or quantify any change in operating or financial results. The material development is the establishment of a potential $100 million equity issuance facility and the immediate issuance of commitment shares.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Any proceeds received are expected to be used for general corporate purposes, but the filing does not provide a detailed allocation or liquidity forecast.
- Actual proceeds will depend on the company’s decisions, market conditions, trading price, sale frequency, and sale prices.
- The company may issue shares only when specified conditions are met, including a prior-day closing price generally at or above a $1.00 threshold and receipt of shares from prior purchases.
- The company may not enter into specified variable-rate transactions during the agreement term, subject to limited exceptions.
- B. Riley agreed not to engage in short sales or hedging transactions establishing a net short position in the common stock during the term.
- The agreement automatically terminates upon specified events, including completion of $100 million in purchases, loss of an eligible exchange listing, certain bankruptcy events, or expiration of the 24-month term. Core Scientific may terminate after commencement with five trading days’ notice and no penalty.
- The common stock issued to B. Riley was issued in reliance on the Section 4(a)(2) and Rule 506(b) exemptions from Securities Act registration. Resale registration rights were provided under a separate agreement.
- Potential future issuances could dilute existing stockholders and may place downward pressure on the common stock price.
Important Facts for Investors to Verify
- Whether the SEC declared the resale registration statement effective and when the facility commenced.
- The number of shares actually sold to B. Riley, the weighted-average prices, discounts, and gross and net proceeds received.
- Remaining availability under the $100 million commitment and the 70,289,880-share Nasdaq Exchange Cap.
- The effect of commitment shares and any subsequent issuances on dilution and B. Riley’s ownership percentage.
- How proceeds were used and whether later filings disclose liquidity, debt, bankruptcy, exchange-listing, or other financial risks.